natgillin/translations-raw huggingface dataset:
In the presence of ombitasvir, paritaprevir exposures were minimally affected (5% to 27% change) while dasabuvir exposures increase by approximately 30%.
Prisotnost ombitasvirja je minimalno vplivala na izpostavljenost paritaprevirju (sprememba za 5 do 27 %), izpostavljenost dasabuvirju pa se je povečala za približno 30 %.
In the presence of oxygen, nitric oxide is rapidly oxidised to derivatives which are toxic to the bronchial epithelium and alveolo-capillary membrane.
V prisotnosti kisika dušikov oksid hitro oksidira v snovi, ki so toksične za epitel bronhijev in alveolo- kapilarne membrane.
In the presence of strong CYP3A4 inducers reduced efficacy of macitentan could occur.
V prisotnosti močnih induktorjev CYP3A4 se lahko učinkovitost macitentana zmanjša.
In the presence of symptoms of hyperammonemia (e.g. nausea, vomiting, lethargy, irritation), ammonia levels should be monitored closely.
V prisotnosti simptomov hiperamoniemije (npr. siljenje na bruhanje, bruhanje, letargija, razdražljivost) moramo pozorno spremljati ravni amoniaka.
In the presence of viral infections, corticosteroids may worsen or hasten the progress of the disease.
Če so prisotne virusne okužbe, lahko kortikosteroidi poslabšajo bolezen ali pospešijo njeno napredovanje.
In the prevention of flu, Tamiflu was studied in patients who had been exposed to the disease when one of their family members contracted flu (962 cases) or during an epidemic (1,562 people aged between 16 and 65 years, and 548 elderly people in nursing homes).
Pri preprečevanju gripe so zdravilo Tamiflu proučevali pri bolnikih, ki so bili izpostavljeni bolezni, ko se je eden od njihovih družinskih članov okužil z njo (962 primerov) ali med epidemijo (1 562 oseb, starih od 16 do 65 let, ter 548 starejših ljudi v domovih za starejše občane).
In the prevention of osteoporosis, women receiving Evista had an increase in bone density in the hip or spine of 1.6% over two years, and those receiving placebo had a decrease of 0.8%.
Pri preprečevanju osteoporoze se je pri ženskah, ki so prejemale zdravilo Evista, v dveh letih gostota kosti v kolkih ali hrbtenici povečala za 1,6 %, pri tistih, ki so prejemale placebo, pa se je zmanjšala za 0,8 %.
In the prevention of porcine colonic spirochaetosis (colitis), Econor in feed at a dose of 1-1.5 mg valnemulin/kg bodyweight/day (i.e.
Pri preprečevanju spirohetoze debelega črevesa pri prašičih (kolitisa) je bilo zdravilo Econor v krmi v odmerku 1–1,5 mg valnemulina/kg telesne mase/dan (tj.
In the prevention of skeletal events, Bondronat is either given as a 6-mg infusion lasting at least 15 minutes every three to four weeks, or as one tablet once a day.
Pri preprečevanju z okostjem povezanih dogodkov se zdravilo Bondronat daje kot 6-miligramska infuzija v trajanju najmanj 15 minut vsake tri do štiri tedne ali kot ena tableta enkrat na dan.
In the prevention of skeletal events, Iasibon is either given as a 6-mg infusion lasting at least 15 minutes every three to four weeks, or as one tablet once a day.
Pri preprečevanju z okostjem povezanih dogodkov se zdravilo Iasibon daje kot 6-miligramska infuzija v trajanju najmanj 15 minut vsake tri do štiri tedne ali kot ena tableta enkrat na dan.
In the prevention studies, Posaconazole SP was as effective as fluconazole in stem cell transplant patients, with 5% of patients developing an infection in the Posaconazole SP group, and 9% in the comparator group.
V raziskavah glede preprečevanja je bilo zdravilo Posaconazole SP pri bolnikih s presaditvijo matičnih celic enako uspešno kot flukonazol – v skupini, ki je prejemala zdravilo Posaconazole SP je okužbo razvilo 5 % bolnikov, v primerjalni skupini pa 9 %.
In the prevention studies, Tamiflu reduced the incidence of flu among the people in contact with a flu patient.
V študijah preprečevanja gripe je zdravilo zmanjšalo pojavnost gripe pri ljudeh, ki so bili v stiku z osebo, obolelo za gripo.
In the prevention study, 2.3% of patients taking Eliquis (2.5 mg twice a day) experienced a clotting event or died, compared with 9.3% of patients taking placebo.
V študiji o preprečevanju so strdek ali smrt zabeležili pri 2,3 % bolnikov, ki so jemali zdravilo Eliquis (2,5 mg dvakrat na dan), v primerjavi z 9,3 % bolnikov, ki so jemali placebo.
In the prevention trials, the percentage of subjects experiencing an increase or decrease in BMD during raloxifene therapy was: for the spine 37 % decreased and 63 % increased; and for the total hip 29 % decreased and 71 % increased.
V preskušanjih preventive osteoporoze so bili odstotki preiskovank, pri katerih so ugotovili povečanje ali zmanjšanje BMD med terapijo z raloksifenom, naslednji: za hrbtenico so pri 37 % preiskovank ugotovili zmanjšanje in pri 63 % povečanje BMD; za celoten kolk so pri 29 % ugotovili zmanjšanje in pri 71 % povečanje BMD.
In the previously treated patients, Imbruvica was also shown to be effective when combined with bendamustine and rituximab.
Pri predhodno zdravljenih bolnikih se je zdravilo Imbruvica izkazalo kot učinkovito tudi v kombinaciji z bendamustinom in rituksimabom.
In the previously treated patients, overall, 95% of bleeds responded to one or two injections of Helixate NexGen into a vein.
V celoti je pri predhodno zdravljenih bolnikih v 95 % primerov krvavitev prišlo do odziva na eno do dve injekciji zdravila Helixate NexGen v veno.
In the previously treated patients, overall, 95% of bleeds responded to one or two injections of Kogenate Bayer into a vein.
V celoti je pri predhodno zdravljenih bolnikih v 95 % primerov krvavitev prišlo do odziva na eno do dve infuziji zdravila Kogenate Bayer v veno.
In the previously untreated patients, about 90% of bleeding episodes responded to treatment with one or two injections into a vein.
Pri predhodno nezdravljenih bolnikih je do odziva na terapijo z eno ali dvema infuzijama v veno prišlo pri približno 90 % krvavitev.
In the primary 48 weeks analysis, the proportion of patients with virologic suppression in the dolutegravir + ABC/3TC arm , was superior to the EFV/TDF/FTC arm, p=0.003, the same treatment difference was observed in subjects defined by baseline HIV RNA level (< or > 100,000 copies/mL).
V primarni analizi po 48 tednih je bil delež bolnikov z virološko supresijo v skupini, ki je prejemala dolutegravir + ABC/3TC, večji kot v skupini, ki je prejemala EFV/TDF/FTC (p=0,003); enako razliko v zdravljenju so opazili pri osebah glede na izhodiščno raven HIV RNA (< ali > 100.000 kopij/ml).
In the primary analysis for DFS in the ITT population, XELOX was shown to be significantly superior to 5-FU/LV (HR=0.80, 95% CI=[0.69; 0.93]; p=0.0045).
V primarni analizi preživetja brez bolezni v populaciji, ki so jo nameravali zdraviti (ITT, intent-to-treat), je bila shema XELOX
In the primary analysis of a study (n = 1,183, 656 patients with wild-type KRAS (exon 2) and 440 patients with mutant KRAS tumours) evaluating panitumumab in combination with infusional
V primarni analizi študije (n = 1.183, 656 bolnikov s tumorjem z divjim tipom KRAS (ekson 2) in 440 bolnikov z mutantnim KRAS) so ocenjevali panitumumab v kombinaciji z infundiranimi
In the primary efficacy analysis, global response in the MITT populations at the end of intravenous therapy, anidulafungin was compared to fluconazole in a pre-specified two- step statistical comparison (non-inferiority followed by superiority).
V primarni analizi učinkovitosti, globalnem odzivu populacij MITT na koncu intravenskega zdravljenja, so anidulafungin in flukonazol primerjali z vnaprej opredeljeno dvostopenjsko statistično primerjavo (neinferiornosti in zatem superiornosti).
In the primary efficacy studies of general populations, 81% of patients reported that tadalafil improved their erections as compared to 35% with placebo.
V primarnih študijah učinkovitosti pri splošnih populacijah je 81% bolnikov poročalo, da je zdravilo Tadalafil Mylan izboljšal njihove erekcije, v primerjavi s 35% pri placebu.
In the primary efficacy studies of general populations, 81% of patients reported that tadalafil improved their erections as compared to 35% with placebo.
V primarnih študijah učinkovitosti pri splošnih populacijah je 81% bolnikov poročalo, da je zdravilo Tadalafil Mylan izboljšalo njihove erekcije, v primerjavi s 35% pri placebu.
In the primary efficacy studies, 75% of intercourse attempts were successful in tadalafil treated patients as compared to 32% with placebo.
V primarnih študijah učinkovitosti je bilo pri bolnikih, zdravljenih z zdravilom Tadalafil Mylan, uspešnih 75% poskusov spolnega odnosa v primerjavi z 32% pri placebu.
In the primary endpoint analysis covering the referred period, the age-adjusted rate (number per subject year) of treatment-requiring bleeds during the rFXIII treatment period was 0.053/year (95% CI: 0.010 - 0.272; model-based estimate corresponding to the mean age of 26.4 years for the 41 patients).
V analizi primarnega opazovanega dogodka, ki je zajela omenjeno obdobje, je bil za starost korigirani delež (število na preiskovanca na leto) krvavitev, ki so med obdobjem prejemanja rFXIII zahtevale zdravljenje, 0,053/leto (95 % interval zaupanja: od 0,010 do 0.272; ocene na podlagi modela ustrezajo povprečni starosti 26,4 leta za 41 bolnikov).
In the primary treatment phases of three phase III active-controlled clinical trials in patients with advanced malignancies involving bone, ONJ was confirmed in 1.8% of patients treated with XGEVA (median exposure of 12.0 months; range 0.1 – 40.5) and 1.3% of patients treated with zoledronic acid.
V fazi primarnega zdravljenja v treh kliničnih preskušanjih III. faze, kontroliranih z zdravilno učinkovino, pri bolnikih z napredovanimi malignomi, ki so zajeli kosti, so osteonekrozo čeljustnice potrdili pri 1,8 % bolnikov, zdravljenih z zdravilom XGEVA (mediana izpostavljenost 12,0 mesecev; razpon 0,1 – 40,5), in pri 1,3 % bolnikov, zdravljenih z zoledronsko kislino.
In the PRoFESS trial, an increased incidence of sepsis was observed with telmisartan compared with placebo.
V primerjavi s placebom se je v preskušanju PRoFESS med zdravljenjem s telmisartanom povečala pojavnost sepse .
In the prospective randomized controlled cardiovascular outcomes study, investigator reported events of hypoglycemia were similar in patients receiving placebo (6.5%) and patients receiving alogliptin (6.7%) in addition to standard of care.
V prospektivni randomizirani nadzorovani študiji kardiovaskularnih izidov so raziskovalci poročali o podobni pojavnosti hipoglikemičnih dogodkov pri bolnikih, ki so poleg standardnega zdravljenja prejemali placebo (6,5 %) in bolnikih, ki so prejemali alogliptin (6,7 %).
In the prospective randomized controlled cardiovascular outcomes study, investigator reported events of hypoglycemia were similar in patients receiving placebo (6.5%) and patients receiving alogliptin (6.7%) in addition to standard of care.
V prospektivni randomizirani nadzorovani študiji kardiovaskularnih izidov so raziskovalci poročali o podobni pojavnosti hipoglikemičnih dogodkov pri bolnikih, ki so poleg standardnega zdravljenja prejemali placebo (6,5 %), in bolnikih, ki so prejemali alogliptin (6,7 %).
In the prospectively defined primary analysis statistical significance was not reached at the primaryefficacy endpoint at week 24.
V prospektivno opredeljeni primarni analizi ni bilo statistično značilnih razlik pri primarnih ciljih študije v 24. tednu.
In the PsA or PSOR clinical studies, the safety profile observed in patients with mild renal impairment was comparable to patients with normal renal function.
V kliničnih študijah PsA ali PSOR je bil varnostni profil, ki so ga ugotovili pri bolnikih z blago okvaro ledvic, primerljiv tistemu pri bolnikih z normalnim delovanjem ledvic.
In the psoriasis studies, delayed hypersensitivity reactions occurred early in the treatment course.
Pri študijah psoriaze so se rekcije pozne preobčutljivosti pojavile v zgodnjih fazah terapije.
In the psoriatic arthritis study, 58% of patients receiving Cimzia 200 mg every two weeks and 52% of patients receiving Cimzia 400 mg every four weeks achieved at least 20% reductions compared with 24% of patients receiving placebo.
V študiji psoriatičnega artritisa je do najmanj 20-odstotnega zmanjšanja prišlo pri 58 % bolnikov, ki so vsaka dva tedna prejemali 200-miligramski odmerek zdravila Cimzia, in pri 52 % bolnikov, ki so vsake štiri tedne prejemali 400-miligramski odmerek zdravila Cimzia, v primerjavi s 24 % bolnikov, ki so prejemali placebo.
In the pump
V črpalki
In the pump, the medicine is stable for 45 days at 37°C.
V črpalki je zdravilo stabilno 45 dni pri temperaturi 37 °C.
In the PURSUIT trial, there were 9 patients who received bolus and/or infusion doses more than double the recommended dose, or who were identified by the investigator as having received an overdose.
V študiji PURSUIT je bilo 9 bolnikov takih, ki so prejeli bolusni in/ali infuzijski odmerek, ki je bil več kot dvakrat večji od priporočenega odmerka, oz. ki so jih raziskovalci označili kot prejemnike prevelikega odmerka.
In the PV population, the CTCAE grade 3 and 4 events were reported in 1.8%, while in the MF patients the frequency was 42.56%.
V populaciji bolnikov s pravo policitemijo so o dogodkih stopnje 3 in 4 po CTCAE poročali pri 1,8 % bolnikov, medtem ko je bila pogostnost teh dogodkov pri bolnikih z mielofibrozo 42,56 %.
In the QD group, 6/75 (8%) patients demonstrated new primary protease inhibitor mutations (codons 30, 32, 48, 50, 82, 84, 90), as did 12/77 (16%) patients in the BID group.
V skupini, ki je prejemala zdravilo 1 x dnevno, je 6/75 (8%) bolnikov pokazalo nove primarne mutacije proteaznih inhibitorjev (kodoni 30, 32, 48, 50, 82, 84, 90), kot tudi 12/77 (16%) bolnikov v skupini, ki je prejemala zdravilo 2 x dnevno.
In the rabbit, nitisinone induced a dose-related increase in malformations (umbilical hernia and gastroschisis) from a dose level 2.5-fold higher than the maximum recommended human dose (2 mg/kg/day).
kuncih je pri odmerkih, večjih od 2,5-kratnega največjega priporočenega odmerka za človeka (2 mg/kg/dan), povzročil od odmerka odvisno povečanje pogostosti malformacij (umbilikalne hernije in gastroshize).
In the rabbit, sodium aminosalicylate had no effects on embryofetal development; however, the doses evaluated were below those proposed clinically.
Pri kuncih natrijev aminosalicilat ni vplival na embriofetalni razvoj, vendar pa so bili proučevani odmerki manjši od klinično priporočenih.
In the randomised active-controlled trial, the PFS at 6 months was significantly greater for TMZ than for procarbazine (21 % vs 8 %, respectively – chi-square p=0.008) with median PFS of 2.89 and 1.88 months respectively (log rank p=0.0063).
V randomiziranem, z učinkovino nadzorovanem preskušanju je bil PFS po 6 mesecih statistično značilno daljši pri TMZ kot pri prokarbazinu (21 % v primerjavi z 8 %, hi-kvadrat, p = 0,008), z mediano vrednostjo PFS 2,89 meseca za temozolomid in 1,88 meseca za prokarbazin (test log. ranga p
In the randomised active-controlled trial, the PFS at 6 months was significantly greater for TMZ than for procarbazine (21% vs 8%, respectively – chi-square p = 0.008) with median PFS of 2.89 and 1.88 months respectively (log rank p = 0.0063).
V randomiziranem, z učinkovino nadzorovanem preskušanju je bilo preživetje brez napredovanja bolezni po šestih mesecih pomembno večje v skupini s TMZ kot v tisti s prokarbazinom (21 % v primerjavi z 8 %, vrednost p testa hi-kvadrat = 0,008), s srednjim preživetjem brez napredovanja bolezni 2,89 v primerjavi z 1,88 meseca (vrednost p testa log rank = 0,0063).
In the randomised active-controlled trial, the PFS at 6 months was significantly greater for TMZ than forprocarbazine (21% vs 8%, respectively – chi-square p = 0.008) with median PFS of 2.89 and 1.88 months respectively (log rank p = 0.0063).
V randomiziranem, z učinkovino nadzorovanem preskušanju je bilo preživetje brez napredovanja bolezni po šestih mesecih pomembno večje v skupini s TMZ kot v tisti s prokarbazinom (21 % v primerjavi z 8 %, vrednost p testa hi-kvadrat = 0,008), s srednjim preživetjem brez napredovanja bolezni 2,89 v primerjavi z 1,88 meseca (vrednost p testa log rank = 0,0063).
In the randomised period of the pivotal studies, anaemia was less frequent in PV patients than in MF patients (43.6% versus 82.4%).
V randomiziranem delu ključnih študij je bila anemija manj pogosta pri bolnikih s pravo policitemijo kot pri bolnikih z mielofibrozo (43,6 % v primerjavi z 82,4 %).
In the randomised period of the pivotal studies, the rate of patients experiencing thrombocytopenia was lower in PV (24.5%) patients compared to MF (69.8%) patients.
V randomiziranem delu ključnih študij je bila trombocitopenija manj pogosta pri bolnikih s pravo policitemijo (24,5 %) kot pri bolnikih z mielofibrozo (69,8 %).
In the randomised period of the pivotal study in PV patients, bleeding events (including intracranial and gastrointestinal, bruising and other bleeding events) were reported in 20% of patients treated with Jakavi and 15.3% patients receiving best available therapy.
V randomiziranem delu ključne študije z bolniki s pravo policitemijo so o krvavitvah (vključno z intrakranialnimi in gastrointestinalnimi krvavitvami, podplutbami in drugimi krvavitvami) poročali pri 20 % bolnikov, ki so prejemali zdravilo Jakavi, in pri 15,3 % bolnikov, ki so prejemali najboljše razpoložljivo zdravljenje.
In the randomised period of the pivotal study in PV patients, neutropenia was reported in two patients (1.8%) of which one patient developed CTCAE grade 4 neutropenia.
V randomiziranem delu ključne študije z bolniki s pravo policitemijo so o nevtropeniji poročali pri dveh bolnikih (1,8 %), od katerih je pri enem prišlo do nevtropenije stopnje 4 po CTCAE.
In the randomised period of the pivotal study in PV patients, one (0.9%) CTCAE grade 3 and no grade 4 urinary tract infection was reported.
V randomiziranem delu ključne študije z bolniki s pravo policitemijo so poročali o enem primeru (0,9 %) okužbe sečil stopnje 3, pri tem pa ni prišlo do nobenega primera okužbe sečil stopnje 4.
In the randomised period of the pivotal study in PV patients, the mean systolic blood pressure increased by 0.65 mmHg in the Jakavi arm versus a decrease of 2 mmHg in the BAT arm.
V randomiziranem delu ključne študije z bolniki s pravo policitemijo se je pri bolnikih z zdravilom Jakavi povprečna vrednost sistoličnega krvnega tlaka zvišala za 0,65 mmHg v primerjavi z znižanjem za 2 mmHg pri bolnikih z najboljšim razpoložljivim zdravilom
In the randomised phase IIb study (C208, stage 2) a higher rate of deaths was seen in the SIRTURO treatment group (12.7%;10/79 patients) compared to the placebo treatment group (3.7%;
V randomizirani študiji faze IIb (C208, stopnja 2) so v skupini, ki je prejemala zdravilo SIRTURO (12,7%; 10/79 bolnikov) opazili večjo stopnjo smrti, kot v skupini, ki je prejemala placebo (3,7%; 3/81 bolnikov).
In the randomised, placebo-controlled study (CP043) 9.4% of 459 PecFent-treated BTP episodes in 73 patients required use of any further (rescue) medicinal products within 60 minutes of dosing.
V randomizirani, s placebom kontrolirani študiji (CP043) je bila pri 9,4 % od 459 epizod BTP, zdravljenih z zdravilom PecFent, pri 73 bolnikih potrebna uporaba kakih drugih (rešilnih) zdravil v 60 minutah po odmerjanju.
In the randomized controlled trials 39/41 (95%) of patients treated with Ruconest reached time to beginning of relief within 4 hours.
V randomiziranih, nadzorovanih študijah je 39/41 (95 %) bolnikov, zdravljenih z zdravilom Ruconest, doseglo čas začetka ublažitve v 4 urah.
In the randomized, double-blind, Phase 3 pivotal FLORENCE (FLO-01) study comparing febuxostat with allopurinol (346 patients undergoing chemotherapy for haematologic malignancies and at intermediate-to-high risk of TLS), only 22 (6.4%) patients overall experienced adverse reactions, namely 11 (6.4%) patients in each treatment group.
V randomizirani, dvojno slepi, pilotski študiji 3. faze FLORENCE (FLO-01), kjer so primerjali febuksostat z alopurinolom (346 bolnikov zdravljenih s kemoterapijo zaradi hematološkega malignega obolenja in s srednje visokim do visokim tveganjem za TLS), je v celoti le 22 (6,4%) bolnikov imelo neželene učinke, in sicer 11 (6,4%) bolnikov v vsaki zdravljeni skupini.
In the rasagiline clinical program overall, 1,361 patients were treated with rasagiline for 3,076.4 patient years.
V kliničnem programu razagilina je bilo 1.361 bolnikov zdravljenih z razagilinom 3.076,4 bolnikov- let.
In the rat carcinogenicity study, benign tumours were found in the small bowel and the extrahepatic bile ducts.
V študiji kancerogenosti na podganah so ugotovili pojav benignih tumorjev v tankem črevesu in ekstrahepatičnih žolčevodih.
In the rat embryofoetal developmental toxicity study, malformations of absence of urinary bladder, absence of thyroid gland, and fusion and misalignment of lumbar and thoracic vertebral elements (central and/or neural arches) were observed at all dosage levels (25, 250, and
V študiji embriofetalne razvojne toksičnosti pri podganah so ugotovili deformacije kot npr. odsotnost sečnega mehurja, odsotnost žleze ščitnice in združitev ter neporavnanost ledvenih in prsnih elementov hrbtenice (osrednji in/ali nevralni lok) pri vseh ravneh odmerkov (25, 250 in
In the rat peri- and post-natal development study with tafamidis, decreased pup survival and reduced pup weights were noted following maternal treatment during pregnancy and lactation at doses of 15 and 30 mg/kg.
V študiji peri- in postnatalnega razvoja s tafamidisom pri podganah so opazili zmanjšano preživetje mladičev in zmanjšano maso mladičev po zdravljenju mater med brejostjo in dojenjem z odmerki in 30 mg/kg.
In the RCC Clinical Trial 1, hyperlipaemia was reported as an adverse event in 27% of patients.
V kliničnem preskušanju RCC 1 so poročali o hiperlipemiji kot neželenem učinku pri 27 % bolnikov.
In the RCC Clinical Trial, a Phase 3 clinical trial for renal cell carcinoma, 26% of patients reported hyperglycaemia as an adverse event.
V kliničnem preskušanju RCC, kliničnem preskušanju 3. faze pri karcinomu ledvičnih celic, je 26 % bolnikov poročalo o hiperglikemiji kot neželenem učinku.
In the RE-SONATE study, which compared dabigatran etexilate to placebo, the rate of MI was 0.1 % for patients who received dabigatran etexilate and 0.2 %for patients who received placebo (see section 4.4.).
V študiji RE-SONATE, v kateri so dabigatran eteksilat primerjali s placebom, je bila stopnja pojavnosti miokardnega infarkta 0,1 % pri bolnikih, ki so jemali dabigatran eteksilat, in 0,2 % pri bolnikih, ki so jemali placebo (glejte poglavje 4.4).
In the RE-SONATE study, which compared dabigatran etexilate to placebo, the rate of MI was 0.1% for patients who received dabigatran etexilate and 0.2 % for patients who received placebo (see section 4.4).
V študiji RE-SONATE, v kateri so dabigatran eteksilat primerjali s placebom, je bila stopnja pojavnosti miokardnega infarkta 0,1 % pri bolnikih, ki so jemali dabigatran eteksilat, in 0,2 % pri bolnikih, ki so jemali placebo (glejte poglavje 4.4).
In the REACH study, 112 patients (6 to 17 years, median age 13.0 years) with moderate to severe, active Crohn’s disease (median paediatric CDAI of 40) and an inadequate response to conventional therapies were to receive 5 mg/kg infliximab at weeks 0, 2, and 6.
V študiji REACH so 112 bolnikom (starim od 6 do 17 let, mediana starost 13,0 let) z zmerno do hudo aktivno Crohnovo boleznijo (mediana vrednost PCDAI = 40) in nezadostnim odzivom na običajne načine zdravljenja dajali 5 mg/kg infliksimaba v tednu 0 ter v 2. in 6. tednu.
In the RECOURSE study, 9.4% of patients in the Lonsurf group received G-CSF mainly for therapeutic use.
V študiji RECOURSE je 9,4 % bolnikov v skupini, zdravljeni z zdravilom Lonsurf, predvsem v terapevtske namene prejelo G-CSF.